Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kala Bio Inc (KALA)

Kala Bio Inc (KALA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,039
  • Shares Outstanding, K 2,816
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,200 K
  • 60-Month Beta -2.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.89
Trade KALA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -4.41
  • Number of Estimates 2
  • High Estimate -4.23
  • Low Estimate -4.58
  • Prior Year -4.36
  • Growth Rate Est. (year over year) -1.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.21 +60.57%
on 06/26/24
7.88 -14.21%
on 07/15/24
+1.56 (+30.00%)
since 06/18/24
3-Month
4.21 +60.57%
on 06/26/24
7.88 -14.21%
on 07/15/24
+0.17 (+2.58%)
since 04/19/24
52-Week
4.21 +60.57%
on 06/26/24
15.94 -57.59%
on 08/02/23
-7.71 (-53.28%)
since 07/19/23

Most Recent Stories

More News
Pre-Market Brief: Stocks Rebound As China Reopening Hopes Boost Sentiment

March S&P 500 futures (ESH23) are trending moderately down -0.07% this morning after three major U.S. benchmark indices finished the regular session in the red as new data on the labor market sparked investors’...

ESH23 : 3,957.05s (-0.09%)
SAND.S.DX : 213.400 (-0.84%)
NFLX : 633.34 (-1.51%)
WBD : 8.67 (+1.76%)
KALA : 6.76 (-1.02%)
TMUS : 182.05 (-0.13%)
JWN : 22.67 (-2.41%)
COST : 838.13 (-0.15%)
Here’s Why Sotera Health Company Stock Just Doubled in a Day

Sotera Health Company (NASDAQ: SHC) is a leading global provider of mission-critical sterilization solutions, lab testing, and advisory services.

SHC : 13.09 (-1.13%)
KALA : 6.76 (-1.02%)
Kala Pharmaceuticals Up 400% In The Past Month, What's Next ?

Kala pharmaceuticals underwent a massive rally over the past few days, and by all indications, the stock price is now headed toward a bottom.

KALA : 6.76 (-1.02%)
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030

EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END

SILO : 2.46 (-29.11%)
BXRX : 0.0218 (+7.39%)
HOTH : 0.8222 (-7.68%)
KALA : 6.76 (-1.02%)
NUWE : 3.80 (-1.81%)
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030

/PRNewswire/ -- According to the Centers for Disease Control and Prevention, arthritis affects approximately one in every four Americans, or 58.5 million...

SILO : 2.46 (-29.11%)
BXRX : 0.0218 (+7.39%)
HOTH : 0.8222 (-7.68%)
KALA : 6.76 (-1.02%)
NUWE : 3.80 (-1.81%)
Pre-Market Brief: Stocks Mixed As COVID Surge in China Weighs On Sentiment

March S&P 500 futures (ESH23) are trending up +0.30% this morning after three major U.S. benchmark indices finished the regular session lower, giving up modest initial gains, as growing fears about a recession...

ESH23 : 3,957.05s (-0.09%)
AAPL : 224.31 (+0.06%)
KALA : 6.76 (-1.02%)
TGTX : 21.00 (-1.08%)
TSLA : 239.20 (-4.02%)
CALM : 65.20 (-0.31%)
HYZN : 0.1491 (-47.50%)
Kala Pharmaceuticals (NASDAQ: KALA) Says FDA Accepted its IND Application for KPI-012 and Treatment of PCED

Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and

KALA : 6.76 (-1.02%)
Pre-Market Brief: Stocks Mixed As Investors Assess China Reopening

March S&P 500 futures (ESH23) are trending up +0.08% this morning after three major U.S. benchmark indices closed mixed in the first day of a holiday-shortened last trading week of the year as higher bond...

ESH23 : 3,957.05s (-0.09%)
TSLA : 239.20 (-4.02%)
JNCE : 1.8800 (-2.59%)
KALA : 6.76 (-1.02%)
UTRS : 0.0120 (+9.09%)
MTEK : 1.6266 (+1.35%)
Pre-Market Brief: Stocks Rebound As China Concerns Ease

December S&P 500 futures (ESZ22) are trending up +0.31% this morning after three major US benchmark indices finished the regular session sharply lower after protests in major Chinese cities against strict...

ESZ22 : 3,871.47s (-0.66%)
AAPL : 224.31 (+0.06%)
NAOV : 0.7630 (-2.05%)
KALA : 6.76 (-1.02%)
TCRT : 4.22 (-1.40%)
SI : 1.2500 (+0.81%)
NXST : 175.37 (-0.62%)
UPS : 145.18 (+0.29%)
Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Received...

KALA : 6.76 (-1.02%)

Business Summary

KALA BIO is a clinical-stage biopharmaceutical company. It focused on the research, development and commercialization of therapies for rare and severe diseases of the eye. The company' s lead product candidate consists KPI-012. KALA BIO, formerly known as Kala Pharmaceuticals Inc., is based in ARLINGTON,...

See More

Key Turning Points

3rd Resistance Point 7.28
2nd Resistance Point 7.13
1st Resistance Point 6.95
Last Price 6.76
1st Support Level 6.62
2nd Support Level 6.47
3rd Support Level 6.29

See More

52-Week High 15.94
Fibonacci 61.8% 11.46
Fibonacci 50% 10.07
Fibonacci 38.2% 8.69
Last Price 6.76
52-Week Low 4.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar